2026 MIDD Webinar Series | Application of MIDD for the Development of Etentamig in Relapsed/Refractory Multiple Myeloma
Includes a Live Web Event on 12/09/2026 at 12:00 PM (EST)
-
Register
- Non-member - $50
- Member - Free!
Etentamig is a BCMA x CD3 bispecific antibody in development for RRMM and AL amyloidosis. The webinar will showcase the MIDD strategies that guided key decisions and advancements: (1) optimal dosing regimen selection for RRMM, including step-up dosing via exposure-response and PK/IL6/CRS analyses; (2) demonstration of no DDIs via an IL-6 PBPK model; (3) repriming/restart therapy guidance after dosing delays using PK simulations; and (4) interplay between sBCMA, free, and total PK using a semi-mechanistic PK/PD model to recommend free PK assay only in future studies. Overall, MIDD successfully guided optimal dosing regimen selection and key regulatory decisions for etentamig.
The MIDD Webinar Series, coordinated by Yash Kapoor and Fulya Akpinar Singh, is a series of webinars focused on shaping the future of drug development and regulatory decision-making sponsored by the ISoP Education Committee. Topics range from MIDD approaches in regulatory submission to pharmacometrics topics that are at the core of model development.
Akshanth Polepally
Research Fellow, Director
Abbvie
Dr. Akshanth Polepally is a Research Fellow and Director at AbbVie with over 15 years of experience in drug discovery, clinical pharmacology, and model-informed drug development (MIDD). At AbbVie, he leads efforts in optimal dose selection and the design and execution of clinical pharmacokinetic and pharmacology studies. He has contributed to multiple successful drug approvals and plays a key role in advancing dose optimization strategies across clinical development programs.
Benjamin Englehardt
Associate Director, Pharmacometrics
Abbvie
Dr. Benjamin Engelhardt is an Associate Director in Pharmacometrics at AbbVie. Over his nine years at AbbVie, he has led the oncology pharmacometrics team and contributed to multiple successful regulatory submissions, applying methods ranging from exposure-response analyses to advanced model-informed drug development. Beyond industry, he is a lecturer at multiple universities, a reviewer for journals including CPT and Nature, and a regular contributor to major scientific conferences and consortia.
Key:
Complete
Next
Failed
Available
Locked